Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Blueprint Medicines Corporation has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 7 examiners across 5 art units, showing distinct examiner assignments with some technical-group overlap. AULAKH, CHARANJIT is the busiest examiner, with 1 pending matter.
The action and examiner counts are equal, so no examiner handles more than one matter in the available profile. Counsel should use matter-specific response strategies while checking whether the shared art units create recurring technical or procedural considerations.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (14%) |
| §103 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting only | 2 (29%) |
| Double-patenting + other | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
| SHIM, DAVID M. | 1 | 58.8% | +58.5% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.1% | +41.1% |
| ENGLISH, CONNOR KENNEDY | 1 | 59.3% | +50.3% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031688 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | TOWNSLEY, SARA ELIZABETH | 49d overdue |
| 18939072 | EGFR INHIBITORS | AULAKH, CHARANJIT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031688 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | TOWNSLEY, SARA ELIZABETH | 49d overdue |
| 18573222 | SALT AND CRYSTAL FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | ENGLISH, CONNOR KENNEDY | 26d |
| 18853933 | EGFR INHIBITORS | SHIM, DAVID M. | — |
| 18849277 | BLU-945 IN COMBINATION WITH OSIMERTINIB FOR THE TREATMENT OF NON-SMALL-CELL LUNG CANCER | HEITMEIER, KENDALL NICOLE | — |
| 18572348 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | O DELL, DAVID K | — |
| 18033931 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | HERNANDEZ, JACKSON J | — |
| Art Unit | Apps |
|---|---|
| 1621 | 3 |
| 1626 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18939072 | EGFR INHIBITORS | AULAKH, CHARANJIT | 1621 | §101Other | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18853933 | EGFR INHIBITORS | SHIM, DAVID M. | 1626 | §112 | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18849277 | BLU-945 IN COMBINATION WITH OSIMERTINIB FOR THE TREATMENT OF NON-SMALL-CELL LUNG CANCER | HEITMEIER, KENDALL NICOLE | 1621 | §103DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18573222 | SALT AND CRYSTAL FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | ENGLISH, CONNOR KENNEDY | 1625 | DP | Non-Final OA | 26d | Pending | Dec 21, 2023 |
| 18572348 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | O DELL, DAVID K | 1621 | §103DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18033931 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | HERNANDEZ, JACKSON J | 1627 | DP | Final Rejection | — | Pending | Apr 26, 2023 |
| 18031688 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | TOWNSLEY, SARA ELIZABETH | 1629 | §103 | Final Rejection | 49d overdue | Pending | Apr 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBlueprint Medicines Corporation has 7 pending office actions as of October 2026, spread across 5 art units and 7 examiners.
Charanjit Aulakh has the most, with 1 of Blueprint Medicines Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
